Autosomal Dominant Hyper-IgE Syndrome

1. Disease Information

Overview. Autosomal dominant hyper-IgE syndrome (AD-HIES) is a rare multisystem primary (inborn-error-of-immunity) immunodeficiency caused by heterozygous dominant-negative loss-of-function variants in STAT3. It is the prototypic "connective-tissue/immune" inborn error: it couples a recognizable immunologic triad — markedly elevated serum IgE, recurrent "cold" staphylococcal skin abscesses, and recurrent pneumonia with pneumatocele formation — with non-immune craniofacial, dental, skeletal, and vascular abnormalities. This combination of an immunodeficiency that also disrupts somatic tissue is what makes STAT3-HIES distinctive among the inborn errors of immunity. The eponym Job syndrome (1966, Davis et al., describing girls with "cold" abscesses, after the biblical Job "smitten with sore boils") predates the unified description by Buckley (1972, adding the facial/skeletal features and high IgE), and the molecular cause (STAT3) was discovered in 2007.

Key identifiers. - MONDO: MONDO:0007818 — hyper-IgE recurrent infection syndrome 1, autosomal dominant (the value already in the YAML; correct). - OMIM: 147060 (HYPER-IgE RECURRENT INFECTION SYNDROME 1, AUTOSOMAL DOMINANT; HIES1). Gene: STAT3 OMIM *102582. - Orphanet: ORPHA:2314 — Autosomal dominant hyper-IgE syndrome due to STAT3 deficiency (under the broader Job syndrome grouping ORPHA:2316). - ICD-10: D82.4 (Hyperimmunoglobulin E [IgE] syndrome). ICD-11: 4A00.20 (Hyper-IgE syndromes). - MeSH: D007589 (Job Syndrome). - HGNC (gene): hgnc:11364 (STAT3).

Synonyms / alternative names: AD-HIES; STAT3-HIES; STAT3 dominant-negative HIES; Job syndrome; Buckley syndrome; HIES type 1; classic/sporadic hyper-IgE syndrome.

Data source character. Information is overwhelmingly disease-level aggregated (curated cohorts from the NIH, French national survey, GeneReviews, and the international HSCT consortium), not EHR/individual-patient registries. The largest well-phenotyped series are single-center/national cohorts of tens to low-hundreds of molecularly confirmed patients.

2. Etiology

Primary cause (genetic). Heterozygous germline dominant-negative variants in STAT3 (signal transducer and activator of transcription 3), chromosome 17q21.2. STAT3 is the shared signaling node for a large family of cytokines (IL-6, IL-10, IL-11, IL-21, IL-22, IL-23, G-CSF, leptin, etc.). The mutant allele produces a full-length but non-functional protein that poisons the wild-type STAT3 in the obligate dimer, so a single mutant allele reduces overall STAT3 activity well below the ~50% expected from simple haploinsufficiency. - Holland et al., NEJM 2007 (PMID:17881745): "heterozygous … mutations in … STAT3 in the majority of patients with the hyper-IgE syndrome." - Minegishi et al., Nature 2007 (PMID:17676033): "Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome." - Asano et al., J Exp Med 2021 (PMID:34137790, PMC8217968): of in-frame variants studied, 128/135 (95%) were experimentally dominant-negative, and all 15 out-of-frame variants were dominant-negative via truncated neoproteins/reinitiation isoforms — i.e., negative dominance, not haploinsufficiency, is the unifying mechanism.

Genetic risk factors. The disorder is monogenic and fully penetrant — there is no separate "susceptibility locus." The relevant genetic facts are the mutational hotspots (below): missense/in-frame deletions clustering in the DNA-binding domain and the SH2 domain of STAT3.

Environmental risk factors. None are required for disease (it is Mendelian). Environmental triggers of complications (not of the disease itself) include colonizing Staphylococcus aureus, Aspergillus/other molds (which colonize pneumatoceles), and Candida. Smoking and recurrent infection accelerate the structural lung disease. No sex predilection (equal M:F).

Protective factors. None established at the genetic level. Clinically, early, lifelong anti-staphylococcal prophylaxis and aggressive skin/airway care are "protective" against the morbidity, and HSCT is curative for the immune phenotype (Section 12).

Gene–environment interaction. The core G×E story is STAT3-dependent Th17/IL-17–IL-22 collapse meeting environmental pathogens: the host is constitutively unable to mount the IL-17/IL-22 mucocutaneous antimicrobial program, so common environmental organisms (S. aureus, Candida albicans, Aspergillus) that are trivial for normal hosts cause recurrent, deep, poorly inflamed infection.

3. Phenotypes

STAT3-HIES is multisystem. Frequencies vary by cohort (NIH, French survey, US series); ranges are given where sources differ. Suggested HPO terms in brackets.

Immunologic / infectious (early-onset, often neonatal–infantile): - Markedly elevated serum IgE, typically >2000 IU/mL (peak often ≫10,000); ~97–100% at some point (may normalize in adults). HP:0003212 (Increased circulating IgE concentration). Onset: infancy. Severity: defining hallmark. - Eosinophilia (>700/µL), ~80–90%. HP:0001880 (Eosinophilia). - Recurrent "cold" cutaneous abscesses (staphylococcal, lacking classic warmth/erythema), ~>80%. HP:0100838 (Recurrent cutaneous abscess formation) / HP:0002744 (cold abscess concept). - Recurrent pneumonia (S. aureus, S. pneumoniae, H. influenzae) with pneumatocele/bronchiectasis from aberrant healing, ~>85% pneumonia; pneumatoceles in a large minority. HP:0006532 (Recurrent pneumonia), HP:0025428/HP:0025427 (pneumatocele), HP:0002110 (Bronchiectasis). Pneumatoceles then become niches for Aspergillus/Pseudomonas/non-tuberculous mycobacteria → fatal hemoptysis/invasive aspergillosis. HP:0002099 (Asthma not typical; rather chronic pulmonary disease). - Chronic mucocutaneous candidiasis (nails, oral, vaginal), ~>80%. HP:0002728 (Chronic mucocutaneous candidiasis). - Newborn/eczematoid dermatitis, often first sign within weeks of life, ~all. HP:0000964 (Eczema) / HP:0000962 (Hyperkeratosis), HP:0011123 (papulopustular eruption). - Mucocutaneous viral disease (recurrent HSV, VZV reactivation, molluscum, warts), variable.

Non-immune connective tissue / skeletal / dental / craniofacial: - Characteristic facies (emerging by adolescence): facial asymmetry, prominent forehead, deep-set eyes, broad nasal bridge/fleshy nasal tip, coarse/"leonine" skin with prominent pores, prognathism, high-arched palate. ~80–100% of adults. HP:0000271 (Abnormal facial shape), HP:0000343 (Long philtrum/coarse), HP:0000218 (High palate). - Retained primary (deciduous) teeth / failure of normal exfoliation, ~> 50–65% (US cohort 41%; molecularly-defined series up to 83% delayed). HP:0006335 (Persistence of primary teeth). - Scoliosis, ~>60% (US cohort ~34%). HP:0002650 (Scoliosis). - Minimal-trauma / pathologic fractures and low bone density, ~40–50%. HP:0002659 (Increased susceptibility to fractures), HP:0000938 (Osteopenia), HP:0000939 (Osteoporosis). - Joint hyperextensibility / hyperextensible joints, common. HP:0001382 (Joint hypermobility). - Craniosynostosis (subset). HP:0001363. - Degenerative joint disease / osteoarthritis, adult.

Neurologic / structural: - Chiari I malformation in ~18–20%. HP:0002308 (Arnold-Chiari type I). - Focal brain hyperintensities (white-matter lesions) ~60–70%, usually clinically silent. HP:0002518 (Periventricular white matter hyperintensities). - Lacunar infarcts/stroke related to vasculopathy (below).

Vascular (under-recognized, prognostically important): - Coronary artery tortuosity/ectasia ~50%, coronary aneurysms in a substantial fraction (≈70% have some coronary abnormality in prospective imaging). HP:0001640 (Cardiomegaly not specific) → better: HP:0004942 (Aortic aneurysm), HP:0025019/coronary-artery aneurysm. Chandesris et al., Circulation 2012 (PMID:22456478). - Cerebral / middle-sized artery aneurysms and arterial tortuosity; risk of myocardial infarction, subarachnoid hemorrhage, ischemic stroke even in young, non-atherosclerotic patients.

GI / other: - Esophageal dysmotility / GERD / eosinophilic esophagitis, >50%. HP:0002020 (Gastroesophageal reflux), HP:0002015 (Dysphagia). - Gastrointestinal candidiasis, colon perforation/diverticulitis (reported).

Onset / severity / progression summary: dermatitis and infections begin in infancy; the somatic (facial, dental, skeletal, vascular) features accrue with age and become diagnostic by adolescence/adulthood. Course is chronic-progressive, dominated long-term by structural lung disease and vascular events.

Quality-of-life impact: chronic skin disease/pruritus, recurrent infections, repeated hospitalization/surgery, chronic lung disease with exercise limitation, fracture/scoliosis-related disability, dental morbidity, and the psychological burden of a visible facial phenotype. No HIES-specific validated QoL instrument; generic tools (SF-36, EQ-5D, PedsQL) apply.

4. Genetic / Molecular Information

Causal gene. STAT3 (hgnc:11364; OMIM *102582; Ensembl ENSG00000168610; 17q21.2). Encodes a 770-aa transcription factor with N-terminal, coiled-coil, DNA-binding, linker, SH2, and C-terminal transactivation domains.

Pathogenic variants. - Type/class: predominantly missense substitutions and small in-frame deletions; out-of-frame/splice variants occur but act through translation-reinitiation neoproteins (Asano 2021). - Mutational hotspots: cluster in the DNA-binding domain (e.g., recurrent p.Val463del, p.Arg382Trp/Gln, p.Val637Met in SH2) and the SH2 domain. Woellner et al., JACI 2010 (PMID:20004785, "Mutations in STAT3 and diagnostic guidelines for hyper-IgE syndrome") catalogued the spectrum and tied genotype to the clinical/IgE phenotype. - Functional consequence: dominant-negative — mutant monomer dimerizes with wild-type and abolishes DNA binding/transactivation; NOT simple loss-of-function/haploinsufficiency, and NOT gain-of-function (germline STAT3 GOF causes a distinct early-onset autoimmunity/lymphoproliferation syndrome — a key contrast). - Allele frequency: essentially absent from gnomAD (private, often de novo, pathogenic alleles); recurrent hotspot alleles arise independently. - Origin: germline; the majority are de novo (sporadic), with autosomal dominant transmission when inherited. Somatic STAT3 variants are unrelated (they appear in LGL leukemia / cancers).

Variant classification (ACMG/AMP). Recurrent hotspot dominant-negative missense/in-frame variants are typically Pathogenic/Likely Pathogenic (PS3 functional, PM1 hotspot, PS4/PP1 if segregating, PM2 absence in gnomAD). ClinVar lists the classic alleles as pathogenic.

Modifier genes / epigenetics / chromosomal abnormalities. No established Mendelian modifier genes; phenotypic variability (even within families) is attributed to which STAT3 target pathways are most disrupted and to stochastic/environmental factors. No recurrent epigenetic mechanism or chromosomal rearrangement is implicated — this is a point-mutation disease.

5. Environmental Information

• Environmental/occupational toxins: not causal.
• Lifestyle: smoking and poorly controlled airway infection worsen structural lung disease; otherwise non-contributory to onset.
• Infectious agents (drivers of morbidity, not cause):
• Staphylococcus aureus (NCBITaxon:1280) — dominant skin/lung pathogen; "cold" abscesses, pneumonia, pneumatoceles.
• Candida albicans (NCBITaxon:5476) — chronic mucocutaneous candidiasis.
• Aspergillus fumigatus (NCBITaxon:746128) and other molds — colonize/invade pneumatoceles; major cause of late mortality (hemoptysis, invasive aspergillosis).
• Pseudomonas aeruginosa, non-tuberculous mycobacteria, Pneumocystis jirovecii (especially post-transplant or with lung damage), and herpesviruses (HSV, VZV, EBV).

6. Mechanism / Pathophysiology

Apex lesion → causal chain.

(0) STAT3 dominant-negative dysfunction. A single heterozygous DNA-binding/SH2-domain variant produces a full-length mutant that dimerizes with wild-type STAT3 and abolishes DNA binding/transactivation across the entire STAT3 cytokine network. GO terms: GO:0007260 (tyrosine phosphorylation of STAT protein, DECREASED downstream output — note phosphorylation itself is often preserved; it is DNA binding/transactivation that fails), GO:0007259 (cell surface receptor signaling pathway via JAK-STAT), GO:0006357 (regulation of transcription). The defect is upstream of everything below.

(1) Collapse of Th17 differentiation → IL-17/IL-22 deficiency (immune arm, the central mechanism). STAT3 is required downstream of IL-6 and IL-23 for RORγt-driven Th17 development. Milner et al., Nature 2008 (PMID:18337720): "impaired T(H)17 cell differentiation" in AD-HIES. Loss of IL-17A/F and IL-22 removes the signals that drive epithelial β-defensin/antimicrobial-peptide production and neutrophil recruitment to skin and lung → susceptibility to S. aureus and Candida. Cell types: CL:0000899 (Th17 cell), CL:0000624 (CD4+ αβ T cell), CL:0000775 (neutrophil), CL:0000066 (epithelial cell). GO: GO:0072539 (Th17 cell differentiation), GO:0097400 (interleukin-17-mediated signaling), GO:0050830 (defense response to Gram-positive bacterium).

(2) Blunted IL-6 acute-phase / inflammatory signaling. Impaired IL-6→STAT3 signaling underlies the paradoxically "cold," under-inflamed abscesses (reduced systemic inflammatory response despite deep infection) and contributes to defective antibody/affinity-maturation responses. Holland 2007 (PMID:17881745): "impaired … responses to … IL-6." GO: GO:0070102 (interleukin-6-mediated signaling pathway), GO:0006953 (acute-phase response).

(3) Dysregulated humoral/atopic balance. Impaired STAT3 (IL-10, IL-21) signaling skews toward IgE class-switching/atopy and impairs memory B-cell generation and specific antibody responses → high IgE plus functionally poor antibody. Cell types: CL:0000787 (memory B cell), CL:0000236 (B cell).

(4) Non-immune connective-tissue/skeletal/dental program failure (somatic arm). Because STAT3 transduces IL-11, leptin, and growth-factor signals in bone, vasculature, and craniofacial tissue, dominant-negative STAT3 disrupts: - Bone: STAT3 normally restrains osteoclastogenesis; its loss → increased osteoclast activity, osteopenia, fractures. Zhang et al. 2005 (PMID:15694417) — hematopoietic STAT3 deletion → increased osteoclastogenesis/osteopenia in mice (MODEL_ORGANISM). GO: GO:0045671/GO:0001503 (osteoclast/ossification), cell type CL:0000092 (osteoclast). - Craniofacial/dental: impaired IL-11→STAT3 signaling links to craniosynostosis, delayed tooth exfoliation, retained primary teeth (parallels IL11RA-deficiency craniosynostosis; Nieminen et al., AJHG 2011, PMID:21741611). - Vasculature: STAT3 deficiency reduces VEGF/HIF-1α-dependent vascular maintenance and dysregulates matrix metalloproteinases (notably MMP-8) and TGF-β/TNF-α responses → arterial tortuosity, ectasia, and aneurysm; mouse data show STAT3/IL-17A blockade worsens aneurysm severity and rupture. Chandesris et al., Circulation 2012 (PMID:22456478). GO:0001525 (angiogenesis), cell types CL:0000115 (endothelial cell), CL:0000192 (vascular smooth muscle cell). - Lung architecture: impaired epithelial repair + MMP dysregulation → pneumatocele/bronchiectasis (aberrant post-pneumonia healing) rather than simple infection.

Upstream vs downstream summary. STAT3 DN (upstream) → branches into (a) Th17/IL-17–IL-22 immune-defense failure (skin/lung/mucosal infection) and (b) IL-6 acute-phase blunting (cold abscesses, antibody defects) on the immune side, and (c) bone/vascular/dental connective-tissue programs on the non-immune side. All downstream phenotypes trace to the single transcription-factor lesion.

Molecular profiling. Transcriptomic studies of patient T cells show loss of STAT3 target-gene induction (RORC, IL17A, IL17F, IL22, retinoic-acid-receptor–related signatures); proteomic/functional assays show normal STAT3 protein and tyrosine phosphorylation but absent DNA binding (the basis of the dominant-negative model). No disease-specific metabolomic/lipidomic signature is established.

7. Anatomical Structures Affected

Organ/system level (primary): skin (UBERON:0002097), lung/respiratory tract (UBERON:0002048; bronchi UBERON:0002185), immune/hematopoietic system (UBERON:0002405), oral cavity/teeth (UBERON:0001091 tooth), skeleton (UBERON:0002481 bone tissue; vertebral column UBERON:0002240), craniofacial skeleton/skull (UBERON:0003129).

Secondary / complication-level: cardiovascular system — coronary arteries (UBERON:0001621), cerebral arteries/aorta (UBERON:0001637 artery); central nervous system/brain (UBERON:0000955) — Chiari I, white-matter lesions; esophagus/GI tract (UBERON:0001043) — dysmotility, candidiasis.

Tissue/cell level: epithelium (skin and airway, CL:0000066), Th17 lymphocytes (CL:0000899), neutrophils (CL:0000775), memory B cells (CL:0000787), osteoclasts (CL:0000092), vascular endothelial (CL:0000115) and smooth-muscle (CL:0000192) cells.

Subcellular level: STAT3 acts in the cytoplasm → nucleus (GO:0005634 nucleus; GO:0005829 cytosol); the functional defect is nuclear DNA binding/transcription (GO:0003700 DNA-binding transcription factor activity).

Localization/lateralization: infections and abscesses are multifocal; vascular and skeletal involvement is typically bilateral/systemic; facial features are roughly symmetric/asymmetric (facial asymmetry is itself a feature).

8. Temporal Development

• Onset: congenital/neonatal-infantile — eczematoid newborn rash and recurrent infections usually within the first weeks–months of life.
• Pattern: chronic, with recurrent episodic infections superimposed.
• Progression/stages: early childhood — dermatitis, abscesses, pneumonias, candidiasis, high IgE; adolescence — emergence of the characteristic facies, retained teeth, scoliosis, fractures; adulthood — dominated by chronic structural lung disease (bronchiectasis/pneumatoceles with mold/Pseudomonas/NTM superinfection) and vasculopathy (coronary/cerebral aneurysms), plus lymphoma risk.
• Rate: slow but cumulative; lifelong chronic disease (not self-limited).
• Critical windows for intervention: infancy/childhood for prophylaxis and dental management; pre-irreversible-lung-damage window for considering HSCT; adult vascular surveillance (every ~3 years) to pre-empt fatal aneurysmal events.

9. Inheritance and Population

• Inheritance: autosomal dominant; majority de novo (sporadic). 50% transmission risk per offspring of an affected parent.
• Penetrance: complete/essentially complete; expressivity variable (intra-familial variability in non-immune features).
• Anticipation / germline mosaicism / founder effects: no genetic anticipation; germline/somatic mosaicism is rare but reported (relevant to recurrence counseling); no classic founder populations — recurrent hotspot alleles arise independently across ethnic groups.
• Carrier frequency / consanguinity: not a recessive carrier disease; consanguinity is not a risk factor (that points instead to the recessive HIES mimics — DOCK8, etc.).
• Epidemiology: rare; prevalence on the order of ~1 in 1,000,000 (some older estimates ~1:100,000). Hundreds of molecularly confirmed cases worldwide.
• Demographics: no sex predilection (M:F ≈ 1:1); reported across all ethnicities/geographies; no endemic geographic clustering.

10. Diagnostics

Clinical scoring. The NIH HIES score (Grimbacher et al., NEJM 1999, PMID:10053177 — "Hyper-IgE syndrome with recurrent infections—an autosomal dominant multisystem disorder") weights 19 clinical/lab findings; >40 points suggests HIES, <20 makes it unlikely. Woellner 2010 (PMID:20004785) refined diagnostic guidelines and showed that low Th17 counts and the genotype improve discrimination.

Laboratory. Serum IgE >2000 IU/mL (often historically much higher); eosinophilia >700/µL; reduced/absent IL-17-producing CD4+ (Th17) cells by flow cytometry (a strong discriminator); variably impaired specific antibody responses; normal-to-reduced memory B cells.

Functional/imaging. Chest CT for pneumatoceles/bronchiectasis; coronary CT/MR angiography and brain MRA for aneurysm surveillance; spine imaging for scoliosis; DXA for bone density; echocardiography.

Genetic testing. The diagnosis is confirmed by identifying a heterozygous dominant-negative STAT3 variant. Approaches: single-gene STAT3 sequencing, HIES/PID gene panels (to include DOCK8, PGM3, ZNF341, IL6ST/IL6R, SPINK5, CARD11, ERBIN, TGFBR), or exome/genome sequencing. Functional confirmation (absent STAT3 DNA binding / dominant-negative assay) supports VUS reclassification.

Differential diagnosis (distinguishing features): - DOCK8 deficiency (AR-HIES): severe cutaneous viral infections (HSV, HPV, molluscum), allergies, early malignancy, no connective-tissue/skeletal/retained-teeth features. → genetics. - STAT3 gain-of-function: early autoimmunity, lymphoproliferation, enteropathy — opposite mechanism. - PGM3 deficiency, ZNF341 (AR STAT3-pathway), IL6ST/IL6R defects, Comèl-Netherton (SPINK5), Wiskott-Aldrich, Omenn, atopic dermatitis with high IgE.

Screening. Not part of routine newborn screening (TREC-based NBS misses HIES). Cascade testing of relatives for a known familial variant; prenatal/PGT possible when the familial variant is known.

11. Outcome / Prognosis

• Life expectancy: historically reduced; with modern prophylaxis many reach adulthood, but median survival is shortened, driven by pulmonary complications and vascular events.
• Leading causes of death: invasive pulmonary fungal infection / hemoptysis from pneumatocele/bronchiectasis (Aspergillus, Pseudomonas, NTM), and vascular catastrophe (MI, aneurysm rupture, ischemic/hemorrhagic stroke).
• Malignancy: increased risk, chiefly non-Hodgkin lymphoma (and EBV-associated lymphoma); surveillance for lymphadenopathy advised.
• Morbidity: chronic lung disease, recurrent fractures/scoliosis, dental disease, repeated surgery.
• Prognostic factors: extent of established structural lung damage, fungal colonization, and presence/severity of vasculopathy.
• Surveillance (per GeneReviews): coronary + cerebral vascular imaging every ~3 years in adults; dental review every 6–12 months in childhood; scoliosis monitoring through adolescence; periodic lung imaging and malignancy vigilance.

12. Treatment

Conventional / supportive (lifelong). - Antistaphylococcal prophylaxis: trimethoprim-sulfamethoxazole (cotrimoxazole) is standard; treat exacerbations with anti-staph agents. MAXO: MAXO:0000058/MAXO:0000059 (antibiotic/antimicrobial therapy). CHEBI: trimethoprim CHEBI:45924, sulfamethoxazole CHEBI:9332. - Antifungal prophylaxis/therapy: itraconazole/voriconazole/posaconazole for Aspergillus and CMC; fluconazole for Candida. MAXO: antifungal agent therapy; CHEBI: itraconazole CHEBI:6076, fluconazole CHEBI:46081. - Skin care: bleach (sodium hypochlorite) baths, chlorhexidine, topical antiseptics/emollients, antihistamines for pruritus. MAXO: MAXO:0000511/topical therapy concepts. - Immunoglobulin replacement (IVIG/SCIG): for selected patients with poor specific antibody/hypogammaglobulinemia (benefit limited/uncertain). MAXO: MAXO:0000841 (immunoglobulin therapy concept). - Pulmonary: airway clearance, aggressive treatment of bronchiectasis; surgical resection of complicated pneumatoceles is high-risk and selective. MAXO: MAXO:0000004 (surgical procedure). - Skeletal/dental: bisphosphonates for low bone density (case-based), orthopedic management of scoliosis/fractures, timely extraction of retained primary teeth. - Vascular: risk-factor control and surveillance; aneurysm management per cardiology/neurosurgery.

Curative — allogeneic HSCT. Increasingly used and the only therapy that corrects the immune phenotype (abolishes infections/abscesses, stabilizes lung disease); it does not reverse established non-immune features (skeletal/dental/connective tissue), and its effect on vasculopathy is uncertain (vascular events still reported post-HSCT). - Worldwide HSCT study (Blood Advances, 2025): 41 patients, median age at HSCT 14 y, 5-year overall survival 93%, event-free survival 90%, with ~87% free of bacterial/fungal respiratory infection afterward. - Harrison/Gennery et al. (J Clin Immunol 2021, PMC8249289): "Hematopoietic stem cell transplantation resolves the immune deficit associated with STAT3-dominant-negative hyper-IgE syndrome." - MAXO: MAXO:0010039 (organ/HSCT transplantation), MAXO:0000827-type bone-marrow-transplant concepts.

Experimental / future. Gene-correction (CRISPR/base-editing of the dominant-negative allele, or allele-specific knockdown to relieve negative dominance) is conceptually attractive but preclinical only; no approved targeted/RNA therapy exists. Pharmacogenomics: azole–drug interactions (CYP3A4) and TMP-SMX hypersensitivity are the practical PGx concerns.

Treatment strategy. Lifelong prophylaxis + skin/airway care from diagnosis; multidisciplinary surveillance (pulmonary, vascular, dental, skeletal, oncologic); consider HSCT before irreversible lung damage, weighing transplant risk against progressive infection.

13. Prevention

• Primary prevention: none possible (Mendelian); genetic counseling and reproductive options (PGT/prenatal testing) when a familial variant is known. MAXO: MAXO:0000079 (genetic counseling).
• Secondary prevention: early diagnosis (Th17 flow + STAT3 sequencing in a child with neonatal eczema, abscesses, high IgE) enables prophylaxis before lung damage; cascade testing of at-risk relatives.
• Tertiary prevention (preventing complications): antibacterial/antifungal prophylaxis, skin antisepsis, vaccination (per IEI guidance; avoid live vaccines if significantly immunocompromised/transplanted), vascular and malignancy surveillance, dental and scoliosis management — the core of day-to-day care.
• Immunization: standard inactivated vaccines recommended; live-vaccine caution.
• Behavioral/public-health/environmental: smoking avoidance, mold-exposure reduction, prompt infection treatment.

14. Other Species / Natural Disease

• Taxonomy: STAT3-HIES as a clinical entity is human (NCBITaxon:9606); no naturally occurring animal counterpart is catalogued in OMIA as a recognized "Job syndrome."
• Orthologous gene: Stat3 is highly conserved — mouse Stat3 (NCBI Gene 20848), rat, zebrafish stat3 orthologs exist. STAT3 is essential and conserved from invertebrates onward.
• Veterinary/natural disease: no established spontaneous animal model of this specific dominant-negative HIES; relevance is via engineered models (Section 15).
• Evolutionary conservation: the IL-6/IL-23→STAT3→Th17/IL-17 axis and STAT3's connective-tissue roles are deeply conserved, which is why mouse models recapitulate core features.

15. Model Organisms

• Mouse (Mus musculus, MGI): the primary system. Constitutive Stat3 knockout is embryonic lethal, so disease modeling uses conditional/tissue-specific deletions and knock-in of human dominant-negative alleles:
• Hematopoietic/T-cell-specific Stat3 deletion → impaired Th17, defective IL-17/IL-22, mucocutaneous infection susceptibility (models the immune arm).
• Dominant-negative STAT3 knock-in mice reproduce reduced Th17 and infection phenotypes.
• Osteoclast/bone: hematopoietic Stat3 deletion → increased osteoclastogenesis and osteopenia (Zhang 2005, PMID:15694417) — models the fracture/bone phenotype.
• Vascular: STAT3/IL-17A blockade worsens aneurysm severity and causes fatal rupture in mouse aneurysm models — supports the vasculopathy mechanism.
• In vitro / cellular: patient PBMC/CD4+ T-cell cultures (absent Th17 differentiation, preserved STAT3 phosphorylation but absent DNA binding); patient-derived iPSCs and reporter assays used to demonstrate dominant-negative inhibition of wild-type STAT3 (the functional assay underpinning Asano 2021, PMID:34137790).
• Phenotype recapitulation: mouse models reproduce Th17/IL-17 immune deficits and the bone/vascular arms well; they incompletely reproduce the full human craniofacial/dental "facies" and the precise human pneumatocele biology.
• Resources: MGI (Stat3 alleles), IMPC/KOMP conditional alleles, patient cell repositories; Cellosaurus for patient lines.

Consolidated Ontology Term Suggestions (for KB population)

• Disease: MONDO:0007818. Gene: hgnc:11364 (STAT3).
• HPO (key): HP:0003212 (↑IgE), HP:0001880 (eosinophilia), HP:0100838 (recurrent cutaneous abscess), HP:0006532 (recurrent pneumonia), HP:0002110 (bronchiectasis), HP:0002728 (chronic mucocutaneous candidiasis), HP:0000964 (eczema), HP:0006335 (persistence of primary teeth), HP:0002650 (scoliosis), HP:0002659 (↑fracture susceptibility), HP:0000938 (osteopenia), HP:0001382 (joint hypermobility), HP:0002308 (Chiari I), HP:0000271 (abnormal facial shape), HP:0000218 (high palate), HP:0002020 (GERD), aortic/coronary aneurysm terms (HP:0004942 and coronary-artery-aneurysm terms).
• GO (processes): GO:0072539 (Th17 differentiation), GO:0097400 (IL-17 signaling), GO:0070102 (IL-6 signaling), GO:0007259 (JAK-STAT signaling), GO:0003700 (DNA-binding TF activity), GO:0050830 (defense response to Gram-positive bacterium), GO:0001525 (angiogenesis).
• CL (cells): CL:0000899 (Th17), CL:0000775 (neutrophil), CL:0000787 (memory B cell), CL:0000066 (epithelial cell), CL:0000092 (osteoclast), CL:0000115 (endothelial cell).
• UBERON: UBERON:0002097 (skin), UBERON:0002048 (lung), UBERON:0001621 (coronary artery), UBERON:0000955 (brain), UBERON:0002481 (bone tissue), UBERON:0001091 (tooth).
• CHEBI (drugs): trimethoprim CHEBI:45924, sulfamethoxazole CHEBI:9332, itraconazole CHEBI:6076, fluconazole CHEBI:46081.
• MAXO (treatments): MAXO:0000058/antimicrobial therapy, antifungal therapy, MAXO:0010039 (transplantation/HSCT), MAXO:0000079 (genetic counseling), MAXO:0000004 (surgery).

Key Citations (verify before YAML use)

Sources consulted: - Human STAT3 variants underlie AD-HIES by negative dominance (J Exp Med 2021, PMC8217968) - STAT3 Hyper IgE Syndrome — GeneReviews (NBK25507) - STAT3 and the Hyper-IgE syndrome — review (PMC3710320) - STAT3 Hyper-IgE Syndrome—an Update and Unanswered Questions (J Clin Immunol 2021) - HSCT for STAT3 HIES: a worldwide study (Blood Advances 2025, PMC12359223) - HSCT resolves the immune deficit in STAT3-DN HIES (PMC8249289) - HSCT and vasculopathy in STAT3-DN HIES (Front Pediatr 2020, PMC7511721) - French national survey (PubMed 22751495) - Mutations in STAT3 and diagnostic guidelines (JACI / Woellner) - The genetics of hyper-IgE syndromes (Front Immunol 2025) - Orphanet: AD hyper-IgE syndrome due to STAT3 deficiency (ORPHA:2314)

Bottom line for the KB entry: the existing YAML's framing (dominant-negative STAT3 → Th17/IL-17–IL-22 collapse + blunted IL-6 + connective-tissue/skeletal/vascular disruption) is mechanistically correct and well-supported. The richest additions to make are: the vasculopathy arm (coronary/cerebral aneurysms, MMP-8/VEGF-HIF mechanism, ~3-yearly surveillance), the bone/dental/craniofacial non-immune phenotypes with frequencies, the NIH diagnostic score + low Th17 diagnostic pillar, the lymphoma risk, and HSCT as the curative-for-immune-phenotype treatment. Remember to re-fetch and substring-verify every PMID with just fetch-reference before committing snippets.